Download MendeleyTwo noncompeting human neutralizing antibodies targeting MPXV B6 show protective effects against orthopoxvirus infections.
Zhao, R., Wu, L., Sun, J., Liu, D., Han, P., Gao, Y., Zhang, Y., Xu, Y., Qu, X., Wang, H., Chai, Y., Chen, Z., Gao, G.F., Wang, Q.(2024) Nat Commun 15: 4660-4660
- PubMed: 38821921
- DOI: https://doi.org/10.1038/s41467-024-48312-2
- Primary Citation of Related Structures:
8XS3 - PubMed Abstract:
The recent outbreak of mpox epidemic, caused by monkeypox virus (MPXV), poses a new threat to global public health. Here, we initially assessed the preexisting antibody level to the MPXV B6 protein in vaccinia vaccinees born before the end of the immunization program and then identified two monoclonal antibodies (MAbs), hMB621 and hMB668, targeting distinct epitopes on B6, from one vaccinee. Binding assays demonstrate that both MAbs exhibit broad binding abilities to B6 and its orthologs in vaccinia (VACV), variola (VARV) and cowpox viruses (CPXV). Neutralizing assays reveal that the two MAbs showed potent neutralization against VACV. Animal experiments using a BALB/c female mouse model indicate that the two MAbs showed effective protection against VACV via intraperitoneal injection. Additionally, we determined the complex structure of B6 and hMB668, revealing the structural feature of B6 and the epitope of hMB668. Collectively, our study provides two promising antibody candidates for the treatment of orthopoxvirus infections, including mpox.
Organizational Affiliation:
CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
